Authors

Latest:

Triple Combination Therapies in RCC: Clinical Trial Insights

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Matthew T. Campbell, MD, MS, The University of Texas MD Anderson Cancer Center

Matthew T. Corso

Latest:

What Oncology and Hematology Fellows Can Do to Reduce Their Loan Debt

While debt from medical school loans is inevitable for most oncology and hematology fellows, there are strategies they can consider to lessen that burden.

Matthew T. Rosenberg, MD, Allegiance Health Systems

Matthew Ulrickson, MD

Latest:

The Biology of Burnout

Burnout is a recurring problem for overworked oncologists and hematologists. This article includes ideas to keep you healthy, engaged, and empathic.

Matthew Yurgelun, MD

Latest:

Dr. Yurgelun on Educating Patients on Genetic Testing for CRC

Matthew Yurgelun, MD, instructor in medicine, Harvard Medical School, Dana-Farber Cancer Institute, explains why oncologists should discuss genetic testing with their patients and family members for colorectal cancer, as well as some of the common risk factors for the disease.

Matthews H. Kulke, MD, Harvard Medical School

Maung Myo Htut, MD

Latest:

Dr. Htut on Immunotherapy in Multiple Myeloma

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of immunotherapy in the treatment of patients with multiple myeloma.

Maura N. Dickler, MD

Latest:

Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer

Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Maurice Perol, MD

Latest:

Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer

Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+ non-small cell lung cancer.

Maurie Markman

Latest:

Time Required to Address Scientific Questions Generates an Information Dilemma

One of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.

Maurie Markman, MD

Latest:

Unique Questions Associated With the Increasing Prominence of Precision/Genomic Medicine in Routine Cancer Care

Maurie Markman, MD, delves into questions regarding precision medicine and genetic testing in cancer.

Maurie Markman, MD, CTCA

Latest:

Dr Markman on the Role of PARP Inhibitors in Ovarian Cancer

Maurie Markman, MD, discusses the unique role of PARP inhibitors in the treatment of patients with ovarian cancer.

Max S. Topp, MD

Latest:

Dr. Topp on the Safety Profile of Glofitamab Plus R-CHOP in DLBCL

Max S. Topp, MD, discusses the safety profile of glofitamab in combination with R-CHOP in patients with diffuse large B-cell lymphoma.

Max S. Topp, MD, University Hospital of Wuerzburg

Max S. Wicha, MD

Latest:

Wicha Sees Potential for Significant Expansion of Anti-HER2 Therapy

Max S. Wicha, MD, is an internationally renowned research expert in the field of breast oncology. His lab was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.

Max Topp, MD, University Hospital of Wuerzburg

Max Vergo, MD

Latest:

The New Medical Oncology/Palliative Medicine Fellowship Track

Medical oncology is a complex field, rich in basic science, mechanism of actions, and cutting-edge clinical investigation but also physical, emotional, social, and existential distress for the patient.

Maximilian Diehn, MD, PhD

Latest:

Dr. Diehn on Next Steps With Liquid Biopsies in Lung Cancer

Maximilian Diehn, MD, PhD, an assistant professor in the Department of Radiation Oncology, Stanford Medicine, discusses some of the next steps researchers are taking with liquid biopsies in the field of lung cancer.

Maximilian Hochmair, MD, Otto Wagner Spital